“With repeated injections of the same neuromodulator, some patients may develop antibodies against the complexing protein ...

Market DriversSeveral key factors are contributing to the rapid expansion of the botulinum toxin market: Growing Demand for ...

Letybo, an acetylcholine release inhibitor and a neuromuscular blocking agent, was approved in March 2024 based on data from three phase 3 trials.

In chronic low back pain, botulinum neurotoxin type A improved patients' pain and functional outcomes vs placebo and other local injection therapies.

Botulinum toxin type A was seen to be safe and effective for treating facial paralysis following surgery, improving facial symmetry.

Islanders are being warned about the risks of having non-surgical cosmetic treatments like dermal fillers from people who are ...